论文部分内容阅读
[目的]探讨血浆p16基因甲基化联合p53抗体水平的检测对非小细胞肺癌早期诊断价值和临床意义。[方法]选择98例非小细胞肺癌患者为实验组,以60名健康者作对照,分别采用巢式甲基化特异性聚合酶链反应法检测其血浆p16基因甲基化,用酶联免疫吸附法(ELISA)检测其血浆p53抗体。[结果]非小细胞肺癌组的p16基因甲基化率(χ2=45.709,P<0.001)、p53抗体表达量(Z=-5.786,P<0.001)、p53抗体定性阳性率(χ2=41.638,P<0.001)均高于健康对照组。p16基因甲基化和p53抗体表达及定性检测对非小细胞肺癌预测诊断的敏感度分别为70.41%和58.16%,特异性分别为85.00%和93.33%,正确指数为0.554和0.515。p16基因甲基化和p53抗体定量联合检测结果对非小细胞肺癌诊断的敏感度为82.56%,特异性为78.33%,正确指数为0.610。p16基因甲基化与p53抗体检测具有相关性(r=0.215,P=0.029)。[结论 ]非小细胞肺癌患者血浆中p16基因甲基化与p53抗体可以作为非小细胞肺癌预测诊断的肿瘤标志物,联合检测的预测敏感度高于单独检测。
[Objective] To explore the value of early detection of plasma p16 gene methylation combined with p53 antibody in the diagnosis of non-small cell lung cancer and its clinical significance. [Methods] Ninety-eight patients with non-small cell lung cancer were selected as experimental group and 60 healthy controls as controls. Methylation of plasma p16 gene was detected by nested methylation-specific polymerase chain reaction The plasma p53 antibody was detected by adsorption method. [Results] The positive rates of p16 gene methylation in non-small cell lung cancer (χ2 = 45.709, P <0.001), p53 antibody (Z = -5.786, P <0.001) were higher than the healthy control group. The sensitivity and specificity of p16 gene methylation and p53 antibody expression detection and qualitative detection in non-small cell lung cancer were 70.41% and 58.16%, respectively, with specificity of 85.00% and 93.33%, respectively. The correct indexes were 0.554 and 0.515 respectively. The combined detection of p16 gene methylation and p53 antibody was 82.56%, specificity was 78.33%, and correctness index was 0.610 for the diagnosis of non-small cell lung cancer. The methylation of p16 gene was correlated with the detection of p53 antibody (r = 0.215, P = 0.029). [Conclusion] The methylation of p16 gene and p53 antibody in plasma of non-small cell lung cancer patients can be used as the tumor markers for the predictive diagnosis of non-small cell lung cancer. The combined detection is more sensitive than the single detection.